Stonepine Capital Management LLC Sells 95,344 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Stonepine Capital Management LLC decreased its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 12.2% during the 4th quarter, Holdings Channel reports. The firm owned 683,530 shares of the company’s stock after selling 95,344 shares during the quarter. scPharmaceuticals comprises 2.0% of Stonepine Capital Management LLC’s holdings, making the stock its 17th largest position. Stonepine Capital Management LLC’s holdings in scPharmaceuticals were worth $2,420,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in SCPH. Rhumbline Advisers lifted its stake in scPharmaceuticals by 20.1% in the fourth quarter. Rhumbline Advisers now owns 42,554 shares of the company’s stock valued at $151,000 after buying an additional 7,112 shares during the period. Corebridge Financial Inc. increased its stake in shares of scPharmaceuticals by 29.0% in the 4th quarter. Corebridge Financial Inc. now owns 19,586 shares of the company’s stock valued at $69,000 after acquiring an additional 4,406 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of scPharmaceuticals during the 4th quarter valued at $66,000. Bank of New York Mellon Corp boosted its stake in scPharmaceuticals by 8.8% during the fourth quarter. Bank of New York Mellon Corp now owns 75,174 shares of the company’s stock worth $266,000 after acquiring an additional 6,051 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in scPharmaceuticals by 110.5% in the fourth quarter. Wells Fargo & Company MN now owns 18,407 shares of the company’s stock worth $65,000 after purchasing an additional 9,663 shares during the period. Institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Price Performance

Shares of SCPH opened at $3.22 on Friday. The business’s fifty day moving average is $2.60 and its 200 day moving average is $3.16. scPharmaceuticals Inc. has a 12-month low of $1.94 and a 12-month high of $5.65. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The stock has a market cap of $169.99 million, a P/E ratio of -1.69 and a beta of 0.17.

scPharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The business had revenue of $11.75 million for the quarter, compared to analyst estimates of $11.63 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. Sell-side analysts anticipate that scPharmaceuticals Inc. will post -1.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on SCPH shares. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a report on Thursday, March 20th. Maxim Group decreased their target price on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 20th.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.